Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Diabetic Macular Edema > Study examines 30-year trends in DR, DME in kids with type 1 diabetes
  • Diabetic Macular Edema

Study examines 30-year trends in DR, DME in kids with type 1 diabetes

Ophthalmology 360

Approximately 20% of children with type 1 diabetes had diabetic retinopathy (DR) in the last decade, according to a study that looked at 30-year trends in DR and diabetic macular edema (DME) in adolescents with type 1 diabetes.

To identify trends, researchers analyzed 5487 complication assessments for 2404 children between the ages of aged 12 and 20 years with diabetes for >5 years. This was stratified by 3 decades (1990-1999, 2000-2009, 2010-2019).

The prevalence of DR and DME were 40% and 1.4%, respectively for 1990-1999; 21% and 0.5%, respectively, for 2000-2009; and 20% and 0.9%, respectively, for 2010-2019.

DR was associated with 1-2 daily injections and multiple injections compared with continuous subcutaneous insulin infusion (CSII), older age, higher HbA1c, longer diabetes duration, overweight/obesity, and higher diastolic blood pressure SDS. DME was associated with 1-2 daily injections, longer diabetes duration, higher diastolic blood pressure SDS, higher HbA1c, and elevated cholesterol.

“These findings support contemporary guidelines for lower glycemic targets, increasing CSII use, and targeting modifiable risk factors including blood pressure, cholesterol, and overweight/obesity,” the authors concluded

Reference

Allen DW, Liew G, Cho YH, et al. Thirty-Year Time Trends in Diabetic Retinopathy and Macular Edema in Youth With Type 1 Diabetes. Diabetes Care. 2022;dc211652. doi: 10.2337/dc21-1652. Epub ahead of print. PMID: 35594057.

 

Share

Related Content

  • Retina

Biosimilar aflibercept-ayyh demonstrates favorable real-world safety and efficacy

  • Retina

Switching to aflibercept 8 mg improved anatomical outcomes in previously treated nAMD

Neovascular Age-related Macular Degeneration: Emerging Therapies With an EYE On Treatment Frequency
  • Retina

Treat-and-extend aflibercept 8 mg improves outcomes in nAMD over 1 year

  • Retina

Intravitreal therapy in nAMD linked to lower depression and anxiety risk

  • Retina

Alternative aflibercept regimens maintained efficacy in wet AMD

  • Retina

Nanoscope Therapeutics is working on the potential first-ever optogenetic therapy for retinal diseases

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon